Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection

R. Diel, D. Goletti, C. Lange, D. Manissero
European Respiratory Journal 2011 38: 1238-1239; DOI: 10.1183/09031936.00099111
R. Diel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Goletti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Lange
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: clange@fz-borstel.de
D. Manissero
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

From the authors:

We thank O. Moran Mendoza for his comment on the joint systematic review and meta-analysis on the role of interferon-γ release assays (IGRAs) for the diagnosis of latent infection with Mycobacterium tuberculosis by the Tuberculosis Network European Trials Group (TBNET) and the European Centre for Disease Prevention and Control (ECDC) [1]. O. Moran Mendoza highlights the as-yet limited knowledge about the positive predictive values of IGRAs for the development of tuberculosis, a standpoint that is also expressed in the new European Union guidance on the use of IGRAs in support of the diagnosis of tuberculosis [2].

In our meta-analysis and systematic review, only studies reporting on the diagnosis of latent infection with M. tuberculosis (LTBI) that used the latest commercially available version of IGRAs were included. Studies that were performed with “in-house” IGRAs, e.g. the studies by Hill et al. [3] and by Bakir et al. [4], were not considered. Although it was not the focus of our review, differences between the studies with commercially available IGRAs and these two studies should be highlighted. Among the 26 contacts who developed active tuberculosis in the study by Hill et al. [3] from Gambia, no clear linkage of secondary tuberculosis cases to the putative index cases could be established. In addition, the authors used a slightly different cut-off for IGRA positivity, limiting direct comparison of the results. Bakir et al. [4] performed a primarily interventional study. Most of the household children and adolescent contacts with a positive tuberculin skin test (TST) or IGRA result received isoniazid preventive chemotherapy for a duration of 6 months. This intervention was ∼60% effective at preventing tuberculosis and, thus, substantially influenced the evaluation of the prognostic value of IGRAs for the development of tuberculosis.

In the European region, two large studies that have addressed the positive predictive value of latest-generation IGRAs for the development of tuberculosis have been published to date. While Diel et al. [5] found a clear superiority of an IGRA over the TST for the development of tuberculosis in household contacts, Kik et al. [6] found IGRAs and the TST equally ineffective at predicting the development of tuberculosis in immigrants to the Netherlands. As the study populations investigated were different and Kik et al. [6] performed IGRAs only when the TST was positive, the results of both studies are not directly comparable.

In countries of low-to-medium tuberculosis prevalence, short-term progression rates to tuberculosis in individuals belonging to tuberculosis risk groups have been reported to range from 3.3% to 12.9% [5–9]. Although the potential cost-effectiveness of an IGRA for the investigation of LTBI has recently been demonstrated in immigrant screening in the UK [10], information on the predictive values of IGRAs for the development of tuberculosis still relies on a small number of at-risk individuals who actually developed tuberculosis. Clearly, more information is needed before general recommendations that IGRAs should replace the TST can be made.

Future prospective studies that will address the role of immunodiagnosis in tuberculosis risk assessment should focus on stratification of subjects into different risk groups and be performed in multiple centres.

There is a striking difference in the positive and negative predictive values of the TST and IGRAs for the diagnosis of tuberculosis. While the negative predictive values for all tests in clinical use are >97%, the positive predictive values are low and the large majority of individuals at risk for the development of tuberculosis with a positive TST and/or IGRA result will not develop tuberculosis. Clinical decision makers in many countries are, therefore, hesitant to advocate consequently for preventive chemotherapy despite positive test results. Biomarkers for the prediction of tuberculosis need to be substantially improved beyond the limited performance of the TST and IGRAs, and treatment duration should be shortened substantially. Advocacy of preventive chemotherapy by caregivers and acceptance by individuals at risk for the development of tuberculosis need to be improved. As a general rule, testing should only be offered to those individuals belonging to at-risk groups to identify those with the highest risk for future tuberculosis development.

Footnotes

  • Statement of Interest

    Statements of interest for R. Diel and D. Goletti can be found at www.erj.ersjournals.com/site/misc/statements.xhtml

  • ©ERS 2011

REFERENCES

  1. ↵
    1. Diel R,
    2. Goletti D,
    3. Ferrara G,
    4. et al
    . Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and systematic review and meta-analysis. Eur Respir J 2011; 37: 88–99.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    European Centre for Disease Prevention and Control. Use of Interferon-γ Release Assays in Support of TB Diagnosis. Stockholm, European Centre for Disease Prevention and Control, 2011.
  3. ↵
    1. Hill PC,
    2. Jackson-Sillah DJ,
    3. Fox A,
    4. et al
    . Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 2008; 3: e1379.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Bakir M,
    2. Millington KA,
    3. Soysal A,
    4. et al
    . Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 2008; 149: 777–787.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Diel R,
    2. Loddenkemper R,
    3. Niemann S,
    4. et al
    . Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011; 183: 88–95.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Kik SV,
    2. Franken WP,
    3. Mensen M,
    4. et al
    . Predictive value for progression to tuberculosis by IGRAs and TST in immigrant contacts. Eur Respir J 2010; 35: 1346–1353.
    OpenUrlAbstract/FREE Full Text
    1. Leung CC,
    2. Yam WC,
    3. Yew WW,
    4. et al
    . T-Spot.TB outperforms tuberculin skin test in predicting tuberculosis disease. Am J Respir Crit Care Med 2010; 182: 834–884.
    OpenUrlCrossRefPubMedWeb of Science
    1. Aichelburg MC,
    2. Rieger A,
    3. Breitenecker F,
    4. et al
    . Detection and prediction of active tuberculosis disease by a whole-blood interferon-γ release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48: 954–962.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Clark SA,
    2. Martin SL,
    3. Pozniak A,
    4. et al
    . Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 2007; 150: 238–244.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Pareek M,
    2. Watson JP,
    3. Ormerod LP,
    4. et al
    . Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011; 11: 435–444.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 38 Issue 5 Table of Contents
European Respiratory Journal: 38 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection
R. Diel, D. Goletti, C. Lange, D. Manissero
European Respiratory Journal Nov 2011, 38 (5) 1238-1239; DOI: 10.1183/09031936.00099111

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection
R. Diel, D. Goletti, C. Lange, D. Manissero
European Respiratory Journal Nov 2011, 38 (5) 1238-1239; DOI: 10.1183/09031936.00099111
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Endothelial to mesenchymal transition as novel feature of pulmonary fibrosis
  • Transitioning endothelial cells contribute to pulmonary fibrosis
  • Treatable traits in ILD: why not consider acute exacerbations?
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society